Zynex, Inc. (ZYXI) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals significant challenges: a sharp revenue decline, ongoing FDA approval delays, and unresolved TRICARE payment issues. The restructuring efforts, while aimed at cost savings, are causing short-term disruptions. Despite a strong balance sheet, the net loss and declining gross profit raise concerns. Management's unclear responses on key issues further contribute to a negative sentiment. With a mid-cap stock, these factors likely result in a negative market reaction, estimated between -2% to -8%.
Key Financial Performance
Net Revenue $22.3 million in Q2 2025 compared to $49.9 million in Q2 2024, a decline primarily due to the temporary payment suspension from TRICARE and slowing order growth impacted by sales force reductions, shipping policy adjustments, and redirection of sales force activity.
Device Revenue $11 million in Q2 2025.
Supplies Revenue $11.3 million in Q2 2025.
Gross Profit $15.2 million or 68% of revenue in Q2 2025 compared to $39.9 million or 80% of revenue in Q2 2024, a decline due to reduced revenue and changes in sales force and shipping policies.
Sales and Marketing Expenses Decreased by 45% to $12.8 million in Q2 2025, primarily due to headcount reduction and focus on sales rep productivity.
General and Administrative (G&A) Expenses $12.7 million in Q2 2025 compared to $14.5 million in Q2 2024, reflecting cost-cutting measures.
Net Loss $20 million or $0.66 per share in Q2 2025 compared to net income of $1.2 million in Q2 2024. Over half of the loss was due to a noncash charge of $10.3 million related to an allowance on deferred tax assets.
Adjusted EBITDA Loss of $8.9 million in Q2 2025 compared to adjusted EBITDA of $3.5 million in Q2 2024, reflecting reduced revenue and operational challenges.
Cash on Hand $17.5 million as of June 30, 2025, with a significant reduction in cash burn during Q2.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NiCO pulse oximeter: Submitted to the FDA in May 2025. It uses laser technology to address accuracy issues in current LED-based pulse oximeters, particularly for patients with darker skin, elevated carbon monoxide, or low blood oxygen levels. Expected FDA clearance in approximately 6 months. Positioned to enter the $3.5 billion global patient monitoring market.
Revenue diversification: Efforts to diversify revenue streams by increasing call points, sales of other products, and end users. Focus on operating without reliance on TRICARE revenue.
Cost reduction: Annualized expense reduction of approximately $40 million through staff reductions, outsourcing, and operational efficiencies.
Sales force restructuring: Realigned sales force to improve productivity, reduced headcount, and revamped compensation model to incentivize performance.
Leadership changes: Appointment of Steven Dyson as new CEO starting August 18, 2025, with a focus on optimizing payer mix and growth trajectory. CFO Dan Moorhead announced resignation.
Strategic refocus: Refocusing the pain management business model, including reshaping the sales force, streamlining corporate structures, and improving supply chain management.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
TRICARE Payment Suspension: The temporary suspension of payments from TRICARE continues, creating revenue uncertainty. The company is unable to predict the resolution timeline, which impacts financial stability and necessitates operational adjustments.
Revenue Decline: Net revenue dropped significantly from $49.9 million in Q2 2024 to $22.3 million in Q2 2025, primarily due to the TRICARE payment suspension and reduced order growth.
Sales Force Reductions: The company has reduced its sales force, which has impacted order growth and revenue generation. This restructuring may have short-term negative effects on sales performance.
FDA Approval Timeline for NiCO Pulse Oximeter: The FDA approval process for the NiCO pulse oximeter is ongoing and expected to take several months. Delays in approval could hinder the company's ability to capitalize on this product's market potential.
Convertible Debt Maturity: The company has $60 million in convertible debt due in May 2026, now classified as a current liability. Refinancing this debt is critical to avoid financial strain.
Operational Restructuring Costs: The company is undergoing significant operational restructuring, including staff reductions and outsourcing, which may lead to short-term disruptions and costs.
Market Competition and Product Accuracy: The NiCO pulse oximeter faces competition in the patient monitoring market. While it claims superior accuracy, market adoption will depend on FDA approval and acceptance by healthcare providers.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future Cash Flow: The company aims to return to positive cash flow by the end of 2025 through cost reductions, improved inventory management, and a diversified customer base.
Cost Savings: Annualized expense reductions of approximately $40 million are anticipated due to staff reductions and operational efficiencies.
New Leadership: Steven Dyson will join as CEO on August 18, 2025, bringing over 25 years of experience in the medical technology sector. He will focus on optimizing the payer mix and driving growth.
FDA Approval for NiCO Pulse Oximeter: The company expects FDA clearance for the NiCO laser pulse oximeter within six months of an additional information request scheduled for August 2025. This product is anticipated to address significant market needs and biases in current pulse oximetry technology.
Sales Force Realignment: The company is restructuring its sales force to improve productivity and align with business objectives. This includes reducing headcount, revising compensation models, and focusing on high-performing representatives.
Revenue Diversification: Efforts are underway to diversify revenue streams by increasing sales of other products and technologies, and targeting a broader range of end users.
Patient Monitoring Market Opportunity: The NiCO pulse oximeter is expected to enter the $3.5 billion global patient monitoring market as a superior product, addressing accuracy issues and skin pigmentation biases in current technologies.
Guidance Suspension: Quarterly guidance has been suspended temporarily as the new CEO and CFO review forecasting procedures.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the timeline for the FDA's response and anticipated approval for NiCO?
A:The FDA's response (AI) is expected in August, and clearance is anticipated six months from then, likely around December.
Q:Is there confidence that there won't be a second AI iteration from the FDA?
A:While there is no certainty about the FDA's actions, the company has forecasted AI questions and prepared responses, expressing confidence in their submission.
Q:What are the next steps and timelines for TRICARE, and how is the patient referral flow?
A:There is no information on TRICARE payment suspension next steps or resolution. The company continues to service TRICARE patients, but the inflow of patients has reduced due to a reduced sales rep headcount.
Q:What are the expectations for sales and marketing and G&A expenses in the second half of the year?
A:Sales expenses are expected to decrease by another 15%-20% in Q3 and then flatten out. G&A expenses are expected to decrease by 10%-12% from Q2 to Q3 and then flatten out, with the full effect of cost reductions visible in Q3.
Q:What details are available about the FDA's data request and their concerns?
A:The FDA is concerned about LED technology and ensuring the company's technology performs as well as or better than LED. They are also reviewing claims positioning and clinical data. The company is prepared to respond quickly to these concerns.
Q:Are there any new initiatives or strategies from the new CEO?
A:The new CEO, Steven Dyson, is focused on aligning the leadership team and refocusing on pain management to improve the company's valuation over the next several years.
Q:Why did revenue come in below the recently provided guidance?
A:Revenue was impacted by TRICARE issues, sales force reduction, and reduced supply shipments due to insurance company allowables and a utilization management control program.
Q:Why is the company still servicing TRICARE patients despite payment issues?
A:TRICARE specifically requested the company to continue servicing patients, including new ones, despite the lack of payments. The company is evaluating this approach but continues to prioritize patient care.
Q:Review of Unclear Management Responses
A:Management avoided providing clear answers on TRICARE payment suspension next steps and resolution timelines, as well as the specific nature of the FDA's data request and concerns.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
DHA
FDA information
Gregg President
NiCO FDA
NiCO laser
Officer Gregg
Research Division
TRICARE patient
accuracy issue
allowance
base
bedside
blood oxygen
bloodstream level
care outcome
cash flow
date
effort sale
experience
head count
improvement
information request
lab
laser pulse
laser technology
level blood
liability
loss noncash
objective
order sale
oximeter market
patent laser
pathway
platform
resolution
role
support
tax
ZYXI Transcript
Zynex, Inc. (ZYXI) Q3 2025 Earnings Call Prepared Remarks Transcript
Unknown11-18
The earnings call reveals significant financial challenges, including a drastic revenue decline, negative cash flow, and asset impairment. Despite efforts to stabilize, uncertainties from government investigations and debt obligations overshadow potential positive developments. The suspension of guidance and liquidity concerns further exacerbate the situation. With no clear resolution in sight and ongoing operational challenges, the stock is likely to experience a strong negative reaction in the short term.
Zynex, Inc. (ZYXI) Q2 2025 Earnings Call Transcript
Unknown7-31
The earnings call reveals significant challenges: a sharp revenue decline, ongoing FDA approval delays, and unresolved TRICARE payment issues. The restructuring efforts, while aimed at cost savings, are causing short-term disruptions. Despite a strong balance sheet, the net loss and declining gross profit raise concerns. Management's unclear responses on key issues further contribute to a negative sentiment. With a mid-cap stock, these factors likely result in a negative market reaction, estimated between -2% to -8%.
Earnings call transcript: Zynex Q1 2025 earnings miss, stock drops 6.73%
Unknown4-29
The earnings call revealed significant challenges, including a revenue decline due to TRICARE payment suspension, increased competition, and regulatory hurdles. Despite cost-saving measures and long-term growth optimism, the lack of guidance for 2025, expected net loss, and unclear TRICARE resolution weigh negatively. The Q&A section underscored uncertainties, particularly around TRICARE payments, which are crucial for revenue recovery. The absence of clear management responses further adds to investor concerns. Given these factors, a negative stock price reaction is expected over the next two weeks.
Zynex, Inc. (ZYXI) Q1 2025 Earnings Call Transcript
Unknown4-29
The earnings call highlights significant challenges: a 43% revenue decline, regulatory issues with TriCare, and operational inefficiencies. The lack of guidance and unclear management responses further exacerbate concerns. Although cost-saving measures and potential new product launches provide some optimism, the immediate outlook remains negative due to the unresolved TriCare suspension and expected net losses. The sentiment in the Q&A indicates uncertainty and skepticism among analysts, leading to a negative stock price prediction in the short term.
ZYXI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
